GEMCITABINE AND CAPECITABINE IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA

吉西他滨和卡培他滨治疗不可切除或转移性胆管癌

• 批准号: 7376317
• 负责人: ALAN D MILLER
• 金额: $ 0.25万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376317
• 关键词: GEMCITABINE; CAPECITABINE; UNRESECTABLE; METASTATIC; CHOLANGIOCARCINOMA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out what effect (good and bad) the combination of the drugs capecitabine and gemcitabine will have on your tumor. This research is being done because right now there is no curative treatment for this type of cancer. Standard chemotherapy causes the tumor to shrink in 10%-15% of people with unresectable gallbladder or cholangiocarcinoma, but those responses last only 3-6 months. Better therapies are needed to treat patients with this disease. The patient will be asked for permission to submit their tissue samples and blood samples to that they may be studied. Scientist will study their tissue to see if they can predict survival by testing certain aspects of their tumor tissue. If they agree, tumor tissue that is left from the biopsy they have before they register to this study will be used for these tests. The blood sample will be taken before they start treatment. A consent form for use of specimens for research has information about using their tissue for research and asks if they will agree to allow us to keep some of the tissue that is left and use it for future studies.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。本研究的目的是找出卡培他滨和吉西他滨药物的组合会对您的肿瘤产生什么影响（好的和坏的）。 正在进行这项研究是因为目前这种类型的癌症还没有治愈方法。标准化疗可使 10%-15% 的不可切除胆囊或胆管癌患者的肿瘤缩小，但这些反应仅持续 3-6 个月。需要更好的疗法来治疗患有这种疾病的患者。 患者将被要求允许提交他们的组织样本和血液样本以供研究。科学家将研究他们的组织，看看他们是否可以通过测试肿瘤组织的某些方面来预测生存率。如果他们同意，他们在注册这项研究之前进行的活检留下的肿瘤组织将用于这些测试。在他们开始治疗之前将采集血样。 使用样本进行研究的同意书包含有关使用他们的组织进行研究的信息，并询问他们是否同意允许我们保留一些剩下的组织并将其用于未来的研究。